754 related articles for article (PubMed ID: 34350893)
1. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Dey M; Singh RK
Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
[TBL] [Abstract][Full Text] [Related]
2. The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
Marschallinger J; Altendorfer B; Rockenstein E; Holztrattner M; Garnweidner-Raith J; Pillichshammer N; Leister I; Hutter-Paier B; Strempfl K; Unger MS; Chishty M; Felder T; Johnson M; Attems J; Masliah E; Aigner L
Neurotherapeutics; 2020 Jul; 17(3):1061-1074. PubMed ID: 32072462
[TBL] [Abstract][Full Text] [Related]
3. Montelukast and Coronavirus Disease 2019: A Scoping Review.
Sharifinejad N; Sharafian S; Salekmoghadam S; Tavakol M; Qorbani M
Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):384-393. PubMed ID: 34418892
[TBL] [Abstract][Full Text] [Related]
4. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
5. As a potential treatment of COVID-19: Montelukast.
Fidan C; Aydoğdu A
Med Hypotheses; 2020 Sep; 142():109828. PubMed ID: 32416408
[TBL] [Abstract][Full Text] [Related]
6. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
Al-Kuraishy HM; Al-Gareeb AI; Almulaiky YQ; Cruz-Martins N; El-Saber Batiha G
Eur J Pharmacol; 2021 Aug; 904():174196. PubMed ID: 34004207
[TBL] [Abstract][Full Text] [Related]
7. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
[No Abstract] [Full Text] [Related]
8. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
Mohamed MZ; Zenhom NM
Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
[TBL] [Abstract][Full Text] [Related]
9. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Copertino DC; Duarte RRR; Powell TR; de Mulder Rougvie M; Nixon DF
J Med Virol; 2021 Jan; 93(1):187-189. PubMed ID: 32658304
[No Abstract] [Full Text] [Related]
10. Montelukast as a potential treatment for COVID-19.
McCarthy MW
Expert Opin Pharmacother; 2023 Apr; 24(5):551-555. PubMed ID: 36927284
[TBL] [Abstract][Full Text] [Related]
11. Montelukast: more than a cysteinyl leukotriene receptor antagonist?
Tintinger GR; Feldman C; Theron AJ; Anderson R
ScientificWorldJournal; 2010 Dec; 10():2403-13. PubMed ID: 21170491
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.
Gan HJ; Harikishore A; Lee J; Jeon S; Rajan S; Chen MW; Neo JL; Kim S; Yoon HS
Antiviral Res; 2021 Jan; 185():104996. PubMed ID: 33309540
[TBL] [Abstract][Full Text] [Related]
13. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.
Kordjazy N; Amini S
Ther Adv Respir Dis; 2024; 18():17534666241232284. PubMed ID: 38504551
[TBL] [Abstract][Full Text] [Related]
14. Levocetirizine and montelukast in the COVID-19 treatment paradigm.
May BC; Gallivan KH
Int Immunopharmacol; 2022 Feb; 103():108412. PubMed ID: 34942461
[TBL] [Abstract][Full Text] [Related]
15. Montelukast in pediatric asthma management.
Walia M; Lodha R; Kabra SK
Indian J Pediatr; 2006 Apr; 73(4):275-82. PubMed ID: 16816486
[TBL] [Abstract][Full Text] [Related]
16. Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/K
Alizamani E; Ghorbanzadeh B; Naserzadeh R; Mansouri MT
Int J Neurosci; 2021 Oct; 131(10):1004-1011. PubMed ID: 32408781
[TBL] [Abstract][Full Text] [Related]
17. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
[TBL] [Abstract][Full Text] [Related]
18. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
19. Montelukast reduces inhaled chlorine triggered airway hyperresponsiveness and airway inflammation in the mouse.
Hamamoto Y; Ano S; Allard B; O'Sullivan M; McGovern TK; Martin JG
Br J Pharmacol; 2017 Oct; 174(19):3346-3358. PubMed ID: 28718891
[TBL] [Abstract][Full Text] [Related]
20. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
